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Introduction {#ehf212068-sec-0004}
============

Acute heart failure (AHF) is the leading cause of hospitalization for patients aged over 65 years in the Western world, and long‐term survival with AHF is dismal. Prolonged QRS duration with or without bundle branch block (BBB) is both frequent and has been associated with increased mortality and morbidity in several studies in chronic heart failure.[1](#ehf212068-bib-0001){ref-type="ref"}, [2](#ehf212068-bib-0002){ref-type="ref"} However, the role of ventricular conduction abnormalities in the pathophysiology and prognosis of AHF is not well established. Only few studies have investigated the prognostic impact of specific types of ventricular conduction abnormalities, that is, right bundle branch block (RBBB) or left bundle branch block (LBBB), in the long‐term survival of AHF, and the findings have been controversial. This may in part be due to differences in the baseline characteristics of the patient cohorts and in the length of follow‐up period.[3](#ehf212068-bib-0003){ref-type="ref"}, [4](#ehf212068-bib-0004){ref-type="ref"}, [5](#ehf212068-bib-0005){ref-type="ref"}, [6](#ehf212068-bib-0006){ref-type="ref"}

Patients with new‐onset (*de novo*) AHF differ significantly in their medical history, clinical presentation, and long‐term survival from those with acutely decompensated chronic heart failure (ADCHF).[7](#ehf212068-bib-0007){ref-type="ref"} Whether differences exist in the prevalence of ventricular conduction abnormalities and their effect on long‐term mortality in a comparison between patients with *de novo* AHF and ADCHF remains unknown. In this study, we aimed to examine the characteristics in the admission electrocardiogram (ECG) in a large multicentre European cohort of patients hospitalized for AHF and to assess the differences in their impact on long‐term prognosis in patients with *de novo* AHF and ADCHF.

Methods {#ehf212068-sec-0005}
=======

Patients {#ehf212068-sec-0006}
--------

Data from two independent prospectively collected cohorts were combined for this analysis. The FINN‐AKVA (Finnish Acute Heart Failure Study) study is a prospective, national multicentre study, which enrolled 620 consecutive patients with AHF in 2004 in Finland.[8](#ehf212068-bib-0008){ref-type="ref"} Vital status at 5 years after the index hospitalization and time of death were obtained from the National Population Registry. The admission ECG was available for 595 (96%) patients. The BASEL V study (B‐type Natriuretic Peptide for Acute Shortness of Breath EvaLuation; 2006--2007) recruited patients presenting to the emergency department with a chief complaint of shortness of breath.[9](#ehf212068-bib-0009){ref-type="ref"} For the present analysis, only patients with an adjudicated diagnosis of AHF (*n* = 387) were included, in all of which the admission ECG was available. These together resulted in a cohort of 982 AHF patients with a mean follow‐up period of 3.9 years (95% CI 3.7--4.0 years); the median follow‐up time was 5 years. The end point of interest was all‐cause mortality. Final AHF diagnosis was confirmed by the local investigators based on all clinical, laboratory, and imaging information.

The ECGs in each cohort were analysed by two to three researchers (medical doctors) specially trained for and assigned to the task. Rhythm and conduction abnormalities were characterized in the admission ECG. RBBB and LBBB were identified by standard criteria.[10](#ehf212068-bib-0010){ref-type="ref"} Intraventricular conduction delay (IVCD) was defined as QRS duration ≥ 110 ms without fulfilling the criteria of either BBB.[11](#ehf212068-bib-0011){ref-type="ref"} Patients with a previous history of heart failure were regarded as ADCHF, whereas the others had *de novo* AHF. All patients provided their written informed consent. Both studies were approved by local Ethics Committees and conducted in concordance with the Declaration of Helsinki.

Statistical analyses {#ehf212068-sec-0007}
--------------------

The statistical analyses were performed with SPSS 21 statistical software (IBM Corp, Armonk, NY, USA). Results are shown as numbers and percentages (%), means with standard deviation (SD) or medians with interquartile range (IQR) for variables not normally distributed. Dichotomous variables were compared using the chi‐square test and continuous variables using Student\'s *t*‐test or the Mann--Whitney *U*‐test as appropriate. Analysis of variance served for multiple group comparisons and was corrected with the Bonferroni method. Mortality analyses were performed using Kaplan--Meier (KM) survival curves and Cox proportional hazard ratios. Hazard ratios (HR) are shown with 95% confidence intervals (CI).

Age, sex, and comorbidities previously shown to associate with prognosis or regarded as clinically significant, such as coronary artery disease, previous myocardial infarction, hypertension, and chronic obstructive pulmonary disease, as well as estimated glomerular filtration rate and smoking, were included in the multivariate models. When analysing all patients as one group, the history of chronic heart failure was also included in the model. Because one‐third of the patients had missing natriuretic peptide values, a separate model including available N‐terminal pro‐B‐type natriuretic peptide (NT‐proBNP) data was built. Rhythm on the admission ECG was tested in a multivariable model but was neither independently associated with outcome nor did it improve the model performance, so it was not retained in further analyses. KM survival curves were plotted with cases alive censored at their latest contact date. Mortality rates at the end of the follow‐up period were estimated with KM survival tables. Groups were compared by the log‐rank test. In all analyses, *P*‐values \<0.05 were regarded as statistically significant.

Validation procedure {#ehf212068-sec-0008}
--------------------

Additional ECG data on 1511 patients with AHF from the Faculty Hospital in Brno, part of the Czech AHEAD registry,[12](#ehf212068-bib-0012){ref-type="ref"} served for validation of the main findings. All patients with data available on QRS duration in their admission ECG (76.9%) were included. Criteria for determining the presence of RBBB, LBBB, or IVCD were the same as in the derivation cohort. The mean follow‐up period was 5.9 years (95% CI 5.8--6.1 years, range 0.0--8.0 years). In the multivariate mortality analyses with Cox proportional hazard ratios, the same variables were included in the models as in the derivation cohort, with the exception of smoking and NT‐proBNP, which were available in only 675 (44.7%) and 72 patients (4.8%), respectively. Instead, a model including left ventricular (LV) ejection fraction (LVEF), which was available in 1421 patients (94.0%), was used.

Results {#ehf212068-sec-0009}
=======

Study population {#ehf212068-sec-0010}
----------------

The patients\' mean age was 75.8 years (95% CI 75.2--76.5), and 474 (48.3%) of them were women; 506 (51.5%) of the patients had *de novo* AHF, and 476 (48.5%) had ADCHF. Patient characteristics and medical history are shown in *Table* [1](#ehf212068-tbl-0001){ref-type="table-wrap"}. Patients with *de novo* AHF were younger and had fewer cardiac comorbidities than did those with ADCHF. AHF was caused more often by acute coronary syndrome (28.9% vs. 18.8%; *P* \< 0.001) and by atrial fibrillation or flutter (27.5% vs. 20.0%; *P* = 0.006) in patients with *de novo* AHF than in those with ADCHF. LVEF was higher in patients with *de novo* AHF than with ADCHF (47% vs. 43%; *P* \< 0.001). Overall, 497 deaths occurred during follow‐up, of which 300 were in the ADCHF group and 197 in the *de novo* AHF group. The mortality rate at 5 years was 61.6%, being significantly higher in patients with ADCHF than with *de novo* AHF (76.3% vs. 47.4%; *P* \< 0.001).

###### 

Characteristics of study population in the subgroups of *de novo* AHF and acutely decompensated chronic heart failure (ADCHF), mean (SD) or *n* (%)

                                   *De novo* AHF   ADCHF        *P*‐value
  -------------------------------- --------------- ------------ -----------
  Age, years                       74.7 (10.9)     77.1 (9.9)   \<0.001
  Range                            39--101         38--96       
  Women                            246 (48.6)      228 (47.9)   0.8
  Medical history                                               
  Hypertension                     303 (59.9)      310 (65.1)   0.09
  Chronic atrial fib./flutter      127 (25.7)      157 (33.3)   0.009
  Coronary artery disease          183 (36.2)      311 (65.3)   \<0.001
  Previous myocardial infarction   71 (14.0)       183 (38.4)   \<0.001
  Dyslipidemia                     144 (28.5)      140 (29.6)   0.7
  Diabetes mellitus                151 (29.8)      153 (32.1)   0.4
  COPD                             85 (16.8)       92 (19.3)    0.3
  Smoking                          85 (16.8)       55 (11.6)    0.02
  BMI (*n* = 718)                  27.3 (6.4)      27.7 (5.9)   0.4
  eGFR, mL/min/1.73 m^2^           65 (30)         55 (26)      \<0.001
  LVEDD; mm (*n* = 530)            54 (9)          58 (12)      \<0.001
  LVEF% (*n* = 638)                47 (15)         43 (17)      \<0.001
  RBBB                             41 (8.1)        33 (6.9)     0.5
  LBBB                             44 (8.7)        82 (17.2)    \<0.001
  IVCD                             67 (13.8)       98 (22.2)    0.001

Atrial fib, atrial fibrillation; BMI, body mass index; eGFR, estimated glomerular filtration rate; COPD, chronic obstructive pulmonary disease; LVEDD, left ventricular end‐diastolic diameter; LVEF, left ventricular ejection fraction.

ECG characteristics {#ehf212068-sec-0011}
-------------------

Sinus rhythm was more common in *de novo* AHF than in ADCHF patients (60.7% vs. 48.7%; *P* \< 0.001) on admission ECG, and atrial fibrillation was more common in those with ADCHF (42.2% vs. 34.5%; *P* = 0.01). Mortality rates at 5 years in patients with sinus rhythm, atrial fibrillation or flutter, and other rhythms did not significantly differ in *de novo* AHF (51.1%, 44.1%, and 34.8%, respectively; *P* = 0.3) or ADCHF (73.7%, 77.6, and 81.6%, respectively; *P* = 0.6). Data on duration of the PQ interval were available only from the FINN‐AKVA cohort and were for 288 (29.3%) patients. The median PQ interval was 160 ms (IQR 140--180 ms) in *de novo* AHF and 180 ms (IQR 160--200 ms) in ADCHF (*P* \< 0.001). In univariate analysis, the increasing duration of PQ‐interval seemed to be associated with increased mortality (unadjusted HR 1.04; 95% CI 1.01--1.08; *P* = 0.02 for each 10 ms increase in the duration), but not when adjusted for age and sex (HR 1.01; 95% CI 0.98--1.05; *P* = 0.5).

Ventricular conduction abnormalities {#ehf212068-sec-0012}
------------------------------------

Median duration on the QRS was 102 ms (IQR 90--126 ms); it was longer in patients with ADCHF than with *de novo* AHF (107 ms, IQR 92--136 ms vs. 100 ms, IQR 88--118 ms; *P* \< 0.001). RBBB was similarly common in ADCHF and *de novo* AHF (6.9% and 8.1%; *P* = 0.5), whereas LBBB and IVCD were more common in ADCHF (17.2% vs. 8.7%; *P* \< 0.001, and 22.2% vs. 13.8%; *P* = 0.001). Characteristics of patients in each group of ventricular conduction abnormality are reported in Supporting Information *Table S1*. Patients with RBBB and LBBB were older than those either with IVCD or without conduction abnormality. Each of the three conduction abnormality was more common in men than in women (RBBB 10.2% vs. 4.6%; *P* = 0.001), (LBBB 15.4% vs. 10.1%; *P* = 0.01), and (IVCD 21.5% vs. 13.9%; *P* = 0.003). Patients with LBBB and IVCD had more often history of coronary artery disease and lower LVEF values than those with RBBB or normal ventricular conduction.

Ventricular conduction abnormalities associated with mortality {#ehf212068-sec-0013}
--------------------------------------------------------------

Mortality during follow‐up was higher in patients with a ventricular conduction abnormality (71.5% vs. 55.1%) than in those with normal QRS width: adjusted HR 1.4 (95% CI 1.1--1.8; *P* = 0.004). However, increasing duration of the QRS (continuous variable) as such was not associated with increased mortality: unadjusted HR 1.02 (95% CI 0.99--1.06; *P* = 0.3) in *de novo* AHF and HR 1.00 (95% CI 0.97--1.03; *P* = 0.8) in ADCHF for each 10 ms increase in QRS duration. We observed higher mortality rates with each 10 ms increase in QRS duration between 100 and 140 ms, but QRS width over 140 ms did not show further increase in mortality. The KM curves in *Figure* [1](#ehf212068-fig-0001){ref-type="fig"} illustrate the differences in survival with RBBB and IVCD between *de novo* AHF and ADCHF, and *Table* [2](#ehf212068-tbl-0002){ref-type="table-wrap"} and *Figure* [2](#ehf212068-fig-0002){ref-type="fig"} summarizes the Cox proportional hazard ratios for mortality with each type of ventricular conduction abnormality in AHF.

![Kaplan--Meier survival curves in patients in *de novo* AHF (left) and ADCHF (right) with and without RBBB (top) and IVCD (bottom). Mortality rates at the end of the follow‐up period for each subgroup are indicated at the end of the curves. Cases censored during follow‐up are depicted with crosses within the lines. *P*‐value for difference between groups by log‐rank test.](EHF2-3-35-g001){#ehf212068-fig-0001}

###### 

Cox proportional hazard ratios (HR) with 95% confidential intervals for mortality for each type of ventricular conduction abnormality in all patients and in the subgroups *de novo* AHF and ADCHF

                  Unadjusted HR       *P*       Adjusted HR         *P*    Adjusted HR, NT‐proBNP included (*n*=607)   *P*
  --------------- ------------------- --------- ------------------- ------ ------------------------------------------- -------
  RBBB, all       1.64 (1.20--2.24)   0.002     1.38 (1.00--1.90)   0.05   1.72 (1.13--2.61)                           0.01
  *De novo* AHF   2.21 (1.42--3.42)   \<0.001   1.54 (0.98--2.42)   0.06   1.93 (1.03--3.60)                           0.04
  ADCHF           1.25 (0.79--1.96)   0.3       1.20 (0.76--1.91)   0.4    1.47 (0.80--2.68)                           0.2
  LBBB, all       1.02 (0.78--1.34)   0.9       0.84 (0.64--1.11)   0.2    0.87 (0.63--1.21)                           0.4
  *De novo* AHF   1.09 (0.66--1.79)   0.7       0.94 (0.62--1.68)   0.9    1.03 (0.53--2.00)                           0.9
  ADCHF           0.83 (0.60--1.15)   0.3       0.77 (0.55--1.08)   0.13   0.80 (0.55--1.18)                           0.3
  IVCD, all       1.43 (1.14--1.80)   0.002     1.27 (1.01--1.59)   0.04   1.55 (1.18--2.04)                           0.002
  *De novo* AHF   1.10 (0.73--1.65)   0.6       1.08 (0.71--1.64)   0.7    1.16 (0.70--1.91)                           0.6
  ADCHF           1.53 (1.16--2.01)   0.003     1.38 (1.04--1.82)   0.03   1.79 (1.28--2.52)                           0.001

Both multivariate models are adjusted for age, sex, coronary artery disease, previous myocardial infarction, hypertension, chronic obstructive pulmonary disease, smoking, and glomerular filtration rate, as well as previous heart failure when all patients were analysed.

![Adjusted Cox proportional hazard ratios (♦) with 95% confidence intervals ![](EHF2-3-35-g003.jpg "image") for each type of conduction abnormality in all patients (solid lines) and in the subgroups of *de novo* AHF and ADCHF (dashed lines) in the derivation cohort**.**](EHF2-3-35-g002){#ehf212068-fig-0002}

The RBBB was related to increased mortality in all patients (adjusted HR 1.7; 95% CI 1.1--2.6; *P* = 0.01) and in particular in those with *de novo* AHF (adjusted HR 1.9; 95% CI 1.03--3.6; *P* = 0.04). In an exploratory analysis categorizing patients by LVEF, the association of RBBB with mortality in *de novo* AHF was stronger in patients with impaired systolic function (LVEF \< 40%) (adjusted HR 3.4; 95% CI 1.1--10.4; *P* = 0.03) than in patients with more preserved LVEF (adjusted HR 1.5; 95% CI 0.7--3.1; *P* = 0.3). In contrast, IVCD was independently predictive of poor prognosis overall (adjusted HR 1.6; 95% CI 1.2--2.0; *P* = 0.002) and pronouncedly in those with ADCHF (adjusted HR 1.8; 95% CI 1.3--2.5; *P* = 0.001). Again, the effect on outcome was related to impairment of LV systolic function, with adjusted HR 2.7 (95% CI 1.6--4.5; *P* \< 0.001) for IVCD in patients with LVEF \< 40% compared with HR 1.2 (95% CI 0.7--2.0; *P* = 0.6) in patients with preserved LVEF.

Validation data {#ehf212068-sec-0014}
---------------

In the validation cohort, 978 patients (64.7%) had *de novo* AHF, and 533 (35.3%) had ADCHF. The mean age of the patients was 70.4 years (SD 12.5), and 636 (42.1%) of them were women. Baseline characteristics of the derivation and validation cohorts are shown in Supporting Information *Table S2*. Compared with the derivation cohort, patients in the validation cohort were younger, were more often men, and had more cardiovascular comorbidities. RBBB was present in 130 patients (8.6%), LBBB in 167 patients (11.1%), and IVCD in 161 patients (10.7%). AHF was caused by acute coronary syndrome more often in the validation than in the derivation cohort (49% vs. 24%; *P* \< 0.001), and the patients in the validation cohort were more often critically ill; cardiogenic shock was present in 14.2% compared with 2.1% in the derivation cohort (*P* \< 0.001).

The total mortality rate during follow‐up in the validation cohort was 65.8% (875 deaths). In *de novo* AHF patients, the mortality rate was 56.6%, and for those with ADCHF, 81.9% (*P* \< 0.001). As in the derivation cohort, the presence of RBBB in the admission ECG was independently associated with increased mortality rate in the *de novo* AHF patients (adjusted HR 1.5, 95% CI 1.1--2.1; *P* = 0.006), but not in the ADCHF patients. In contrast, IVCD was independently associated with increased mortality rate in patients with ADCHF (adjusted HR 1.5, 95% CI 1.1--2.0; *P* = 0.007), but not in those with *de novo* (Supporting Information *Figure S1*). Overall, these results were very similar to the derivation cohort, as illustrated also by the KM survival curves in Supporting Information *Figure S2*. Again, the associations to mortality were stronger in patients with impaired LV function (LVEF \< 40%). More specifically, for the *de novo* patients with RBBB, the adjusted HR was 2.0 (95% CI 1.3--3.3; *P* = 0.003) if LVEF \< 40%, while in patients with preserved LVEF, the adjusted HR was 1.4 (95% CI 0.90‐2.03; P= 0.1). For the ADCHF patients with impaired systolic function (LVEF \< 40%) the adjusted HR for IVCD was 1.7 (95% CI 1.2‐2.4; P = 0.002) compared with adjusted HR 1.2 (95% CI 0.7--2.1; *P* = 0.5) if LVEF was preserved.

Discussion {#ehf212068-sec-0015}
==========

This study shows the association of different types of ventricular conduction abnormalities with mortality in AHF. In addition, differences in ventricular conduction abnormalities between *de novo* AHF and ADCHF patients are here described, to our knowledge, for the first time. The data come from a large multicentre European cohort of patients hospitalized for AHF with long‐term mortality follow‐up, and the main results are validated in a large, independent cohort of AHF from another European centre. We show that RBBB is associated with increased mortality, in particular in patients with *de novo* AHF. In contrast, IVCD is an independent predictor of poor prognosis in patients with ADCHF. The effect on mortality of both conduction abnormalities are related to impairment of LV systolic function. LBBB was not associated with poorer long‐term survival overall, or in either of the patient subgroups. These results remained very similar in the validation cohort, even though the patient characteristics differed slightly, and the clinical picture of AHF was more severe and more often induced by acute coronary syndrome compared with the derivation cohort.

The prevalence of RBBB and LBBB in this study was similar to other studies of AHF.[5](#ehf212068-bib-0005){ref-type="ref"}, [6](#ehf212068-bib-0006){ref-type="ref"} Few studies of AHF have analysed IVCD as such, especially with the use of QRS duration ≥110 ms as the definition for IVCD, as we did. Recent reports have, however, suggested that even QRS duration between 110 and 120 ms is associated with adverse outcome in other populations,[11](#ehf212068-bib-0011){ref-type="ref"}, [13](#ehf212068-bib-0013){ref-type="ref"}, [14](#ehf212068-bib-0014){ref-type="ref"} and furthermore, QRS duration around 110 ms also corresponded to optimal cut‐off for worse survival in our cohort (data not shown). Nevertheless, IVCD prevalence in this study is consistent with that in earlier observations regarding increased QRS duration.[1](#ehf212068-bib-0001){ref-type="ref"} Comparing *de novo* and ADCHF patients, we found that the QRS duration was longer and that IVCD as well as LBBB were more frequent in the latter group. RBBB in both groups, in contrast, was almost equally common. Of note, even in *de novo* AHF, prevalence of ventricular conduction abnormalities is markedly higher than in the general population.[13](#ehf212068-bib-0013){ref-type="ref"}

The RBBB, as we show, was a predictor of long‐term mortality in patients with *de novo* AHF. *De novo* AHF and ADCHF patients with RBBB had similar mortality rates, but ADCHF patients showed no increased risk of death associated with RBBB, as their overall mortality was high. Abdel‐Qadir *et al*. found RBBB to be a predictor of mortality in AHF patients, but in their study, it merely reflected the older age and comorbidities of their patients with RBBB, rather than being an independent risk factor for mortality.[6](#ehf212068-bib-0006){ref-type="ref"} Here, RBBB was related to increased mortality especially in *de novo* AHF patients, who were younger and had fewer comorbidities, and even when adjusted for age, sex, medical history, and NT‐proBNP, the strength of this association persisted. RBBB has been associated with previous myocardial infarctions,[5](#ehf212068-bib-0005){ref-type="ref"} increased systolic pulmonary artery pressure,[15](#ehf212068-bib-0015){ref-type="ref"} and right ventricle (RV) dysfunction in chronic heart failure patients.[16](#ehf212068-bib-0016){ref-type="ref"}, [17](#ehf212068-bib-0017){ref-type="ref"} RV dysfunction is an independent predictor of worse survival in chronic heart failure,[18](#ehf212068-bib-0018){ref-type="ref"}, [19](#ehf212068-bib-0019){ref-type="ref"} and recently also found in AHF.[20](#ehf212068-bib-0020){ref-type="ref"} In that study of consecutively recruited AHF patients, RV dysfunction was found to be present in as much as a fourth of patients, and 70% of them also had pulmonary hypertension assessed with echocardiography.

In our study, while the patients with RBBB in general had higher LVEF values than all other patient groups, the negative impact of RBBB on survival seemed to be stronger in those with reduced LVEF, as observed in earlier studies as well.[5](#ehf212068-bib-0005){ref-type="ref"}, [15](#ehf212068-bib-0015){ref-type="ref"}, [21](#ehf212068-bib-0021){ref-type="ref"} Indeed, the presence of RBBB in manifest LV heart failure may reflect a more severe underlying cardiac disorder with more markedly impaired LV function. Constantly elevated LV filling pressures and secondary pulmonary hypertension leading to a biventricular failure through LV--RV coupling mechanisms negatively impact long‐term prognosis.[3](#ehf212068-bib-0003){ref-type="ref"}, [22](#ehf212068-bib-0022){ref-type="ref"} Furthermore, in the setting of AHF, RBBB might be an indicator of acute RV pressure overload induced also by hypoxia‐triggered increase in pulmonary vascular resistance.[3](#ehf212068-bib-0003){ref-type="ref"}, [23](#ehf212068-bib-0023){ref-type="ref"} These considerations might partly explain the lack of association of RBBB with increased risk of adverse outcomes in other populations.[14](#ehf212068-bib-0014){ref-type="ref"}, [24](#ehf212068-bib-0024){ref-type="ref"}, [25](#ehf212068-bib-0025){ref-type="ref"}

Contrary to some earlier reports,[4](#ehf212068-bib-0004){ref-type="ref"}, [6](#ehf212068-bib-0006){ref-type="ref"} in our study, LBBB was not associated with poorer long‐term survival overall, or in either of the patient subgroups. In general, LBBB is associated with advanced LV dysfunction and systolic heart failure.[21](#ehf212068-bib-0021){ref-type="ref"}, [24](#ehf212068-bib-0024){ref-type="ref"}, [25](#ehf212068-bib-0025){ref-type="ref"}, [26](#ehf212068-bib-0026){ref-type="ref"} Even so, in our study, patients with LBBB had the lowest LVEF but were not at increased risk of death even in univariate analysis. In current guidelines,[27](#ehf212068-bib-0027){ref-type="ref"}, [28](#ehf212068-bib-0028){ref-type="ref"} LBBB and mechanical dyssynchrony are targets for cardiac resynchronization therapy to improve prognosis in chronic heart failure. However, in the setting of acute cardiac decompensation, LBBB may simply reflect the severity of cardiac disease and comorbidities, as Tabrizi *et al.* [29](#ehf212068-bib-0029){ref-type="ref"} showed in highly symptomatic chronic HF patients and Stenestrand *et al.* [30](#ehf212068-bib-0030){ref-type="ref"} in acute myocardial infarction patients with LBBB having no additive prognostic value.

Each episode of decompensation is known to substantially worsen the long‐term survival in heart failure.[31](#ehf212068-bib-0031){ref-type="ref"} Furthermore, there has been increasing focus on the importance of time‐to‐therapy for prognosis in AHF.[32](#ehf212068-bib-0032){ref-type="ref"}, [33](#ehf212068-bib-0033){ref-type="ref"} Symptoms of LV decompensation (i.e. dyspnea) may trigger earlier and more aggressive medical interventions in the emergency setting compared with those with peripheral edema (venous congestion and RV failure) as principal sign and symptom of decompensation. In addition, because LBBB is currently a well‐recognized marker of cardiac disease by healthcare providers, this may influence both immediate and long‐term management. Our data suggest that the presence of any conduction abnormality should be regarded as associated with worse prognosis in AHF.

Finally, in the present study, IVCD was more common than either LBBB or RBBB, and almost as frequent as any BBB in AHF. IVCD, like LBBB, has been related to older age, comorbidities, and advanced LV dysfunction.[34](#ehf212068-bib-0034){ref-type="ref"} Prolonged QRS has, however, been independently associated with increased mortality both in chronic heart failure[35](#ehf212068-bib-0035){ref-type="ref"} and in AHF.[2](#ehf212068-bib-0002){ref-type="ref"} Our study contributes to knowledge of the role of IVCD as a prognostic marker in AHF with three important findings. First, we have extended the effect of QRS prolongation on mortality in AHF to include patients with QRS ≥ 110 ms. Secondly, we found that its detrimental effect on prognosis mainly affected patients with ADCHF. Finally, our results suggest that prolonged QRS duration without BBB associates with mortality in patients with evident LV systolic dysfunction. We hypothesize that IVCD is a subtle marker of general myocardial incapability, or electrical failure, which reflects ventricular contractility and in the long term increases the risk of death. Moreover, as a marker of disturbed conduction in the ventricles, QRS prolongation may predispose to arrhythmic or sudden death.[11](#ehf212068-bib-0011){ref-type="ref"}, [13](#ehf212068-bib-0013){ref-type="ref"} These effects become evident only with longer exposure, such as in patients with previous history of heart failure or with long‐term follow‐up, or both.

Limitations {#ehf212068-sec-0016}
===========

We acknowledge that our study has some limitations. Five‐year follow‐up data were not available for the entire study population, but the validation cohort had a mean follow‐up of more than 5 years. In addition, high mortality rates in the study population further limited the number of patients with complete follow‐up times. Especially for RBBB, the numbers of patients and events in the subgroup analyses were small and should be interpreted cautiously. There were no data on pulmonary pressures in the studied cohorts. Data on specific causes of death, especially cardiac or sudden death, would have been of value in addition to all‐cause mortality. Finally, echocardiography was not mandatory during the index hospitalization, and data on LVEF were available in only two‐thirds of the patients in the derivation cohort. However, while NT‐proBNP was measured in very few patients in the validation cohort, the majority had LVEF measured, which strengthens our observations on the association between ventricular conduction abnormalities, LVEF, and outcome.

Conclusions {#ehf212068-sec-0017}
===========

In patients hospitalized for AHF, ventricular conduction abnormalities are common. The prevalence of RBBB, LBBB, and IVCD (QRS ≥ 110 ms) differs between *de novo* AHF and ADCHF. RBBB and IVCD are associated with poor long‐term prognosis and should be considered in the risk stratification of patients hospitalized for AHF. RBBB indicates poor survival particularly in patients with *de novo* AHF, whereas IVCD is an independent predictor of death in patients with ADCHF. The effect of these ventricular conduction abnormalities on prognosis seems to be related to LV systolic dysfunction.
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**Figure S1.** Adjusted Cox proportional hazard ratios (♦) with 95% confidence intervals (‐‐‐) for each type of conduction abnormality in all patients (solid lines) and in the subgroups of *de novo* AHF and ADCHF (dashed lines) in the validation cohort.

**Figure S2.** Kaplan--Meier survival curves of patients with *de novo* AHF (left) and ADCHF (right) in the validation cohort with and without RBBB (above) and IVCD (below). Cases censored during follow‐up are depicted with crosses.
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